A5006117950- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- T-cell and Retrovirus Studies
- HER2/EGFR in Cancer Research
- Acute Lymphoblastic Leukemia research
- Multiple and Secondary Primary Cancers
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Histone Deacetylase Inhibitors Research
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2009-2024
Kettering University
2020-2023
University of California, San Diego
2021
Weill Cornell Medicine
2018
Leukemia and Lymphoma Society
2005-2017
University of Rochester Medical Center
2016
Fred Hutch Cancer Center
2016
Cancer Research Center
2016
NewYork–Presbyterian Hospital
2016
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.We conducted open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (A+AVD) 670 bleomycin, (ABVD). The primary end point was modified progression-free survival (the time progression, death,...
To determine the antitumor activity of novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL).Patients MCL were eligible. Bortezomib was given at a dose 1.5 mg/m2 on days 1, 4, 8, 11. Patients required to have received no more than three prior chemotherapy regimens, least 1 month since treatment, 3 months from rituximab, 7 corticosteroids; absolute neutrophil count 1,500/microL (500/microL if documented bone marrow involvement); platelet...
Abstract Nonparametric maximum likelihood estimation of the probability failing from a particular cause by time t in presence other acting causes (i.e., cause-specific failure probability) is discussed. A commonly used incorrect approach to take 1 minus Kaplan-Meier (KM) estimator (1 – KM), whereby patients who fail extraneous are treated as censored observations. Examples showing extent bias using 1-KM presented clinical oncology data. This can be quite large if data uncensored or...
PURPOSE In studies of diffuse large B-cell lymphoma, positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles chemotherapy has demonstrated prognostic significance. However, some patients treated immunochemotherapy experience a favorable long-term outcome despite positive interim FDG-PET scan. To clarify the significance scans, we prospectively studied FDG-positive disease within risk-adapted sequential program. PATIENTS AND METHODS From March...
Purpose Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine utility of response-adapted therapy for stage III IV classic Hodgkin lymphoma. Patients Methods The Southwest S0816 (Fludeoxyglucose F 18-PET/CT Imaging Combination...
Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits first-line therapy brentuximab vedotin, CD30-directed antibody–drug conjugate, plus doxorubicin, vinblastine, and dacarbazine (A+AVD), as compared bleomycin, (ABVD). A planned interim analysis indicated potential benefit regard to overall survival; data from median of 6 years are now available.
We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550).Transplant eligible patients with rel/ref cHL following first-line were treated two to four cycles of (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 8), vinorelbine (20 (15 mg/m2, given on 21-day cycles. The...
Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival based on lines of treatment remains poorly described in the post-rituximab era. Also, Follicular Lymphoma International Prognostic Index (FLIPI) score was developed to predict at diagnosis, yet it unknown whether increase FLIPI following an initial observation period is associated less-favorable outcomes. To address these knowledge gaps, we retrospectively studied 1088...
This study investigated the efficacy, toxicity, and pharmacokinetic interactions resulting from simultaneous combination chemotherapy highly active antiretroviral therapy (HAART) for patients with human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma (NHL). In addition, effects on viral load, CD4 counts, opportunistic infections were examined use of combined HAART.Sixty-five previously untreated measurable disease at any stage HIV-associated NHL intermediate or high grade...
PURPOSE This phase III, placebo-controlled, randomized trial was designed to investigate efficacy and safety of two doses denileukin diftitox (DD; DAB(389)-interleukin-2 [IL-2]), a recombinant fusion protein targeting IL-2 receptor-expressing malignant T lymphocytes, in patients with stage IA CD25 assay-positive cutaneous T-cell lymphoma (CTCL), including the mycosis fungoides Sézary syndrome forms disease, who had received up three prior therapies. The primary end point overall response...
Review of prognostic factors at Memorial Hospital in New York City has shown that adult patients with large-cell lymphoma (diffuse histiocytic by Rappaport classification) who have high lactic dehydrogenase (LDH) and/or bulky mediastinal or abdominal disease are destined to do poorly conventional combination chemotherapy, a 2-year disease-free survival about 20%. Patients relapse after chemotherapy similar poor prognosis. Thirty-one such were studied evaluate the efficacy intensive...
Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated efficacy relapsed and refractory HL.Patients with HL who were ineligible for autologous stem-cell transplantation (ASCT), or whom this treatment failed, received 120 mg/m(2) as a 30-minute infusion on days 1 2 every 28 growth factor support. The primary end point was overall response rate (ORR). A secondary referral to allogeneic (alloSCT) patients deemed eligible alloSCT at time...
The initial promising results with alternating chemotherapy regimens (mechlorethamine, vincristine, procarbazine, and prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine [MOPP/ABVD]; lomustine, melphalan, vindesine [CAD] plus MOPP ABV) combined intermediate-dose radiation therapy (RT) have been sustained further follow-up; 82.2% of patients (152 185) achieved a complete remission (CR), overall survival is 71.7% +/- 4.4% at 8 years (median follow-up 55 months among the survivors). No...